Yunnan Botanee Bio-Technology Group Co

Yunnan Botanee Bio-Technology Group Co Current Assets

The Current Assets of Yunnan Botanee Bio-Technology Group Co (300957.SZ) as of Nov 3, 2026 is 691.60 M CNY. In the previous year, Current Assets was 6.27 B CNY — a change of -88.97% (lower).

Current Assets

691.60 MCNY

YoY

-88.97%

Last updated:

Current Assets of Yunnan Botanee Bio-Technology Group Co is 2025 691.60 M CNY. Current Assets of Yunnan Botanee Bio-Technology Group Co was 2024 6.27 B CNY. It decreases by -88.97% lower compared to the previous year.

The Yunnan Botanee Bio-Technology Group Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
657.19 M CNY
Jan 1, 2019
940.99 M CNY
Jan 1, 2020
1.40 B CNY
Jan 1, 2021
6.78 B CNY
Jan 1, 2022
6.24 B CNY
Jan 1, 2023
5.96 B CNY
Jan 1, 2024
6.27 B CNY
Jan 1, 2025
691.60 M CNY
The Yunnan Botanee Bio-Technology Group Co Current Assets history
YEARCurrent AssetsYoY
691.60 MCNY-88.97%
6.27 BCNY+5.18%
5.96 BCNY-4.43%
6.24 BCNY-8.02%
6.78 BCNY+383.88%
1.40 BCNY+48.91%
940.99 MCNY+43.18%
657.19 MCNY+42.95%
459.74 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Yunnan Botanee Bio-Technology Group Co Stock analysis

What does Yunnan Botanee Bio-Technology Group Co do? Yunnan Botanee Bio-Technology Group Co., Ltd. generates revenue through the research, development, manufacture, and sales of skin care products and services. The company's product portfolio includes creams, skin care lotions, facial masks, essences, lotions, and makeup items such as isolation creams, blemish balm (BB) creams, and makeup removers. Additionally, it offers medical device products like hyaluronic acid repairing biofilm and hyaluronic acid repairing dressings, designed for skin barrier protection post-minimally invasive surgery. Sales are driven by both offline and online channels, with the firm focusing on these distribution methods as key revenue streams. The company targets consumers seeking skincare solutions, particularly those requiring post-surgical skin care, through its medical device line. Its product range caters to a broad market segment, including daily skincare users and individuals needing specialized care for skin conditions. The firm's emphasis on both conventional skincare and medical-grade products allows it to address diverse consumer needs across multiple segments. Yunnan Botanee's revenue model relies on direct sales of its skincare and medical device products, with no mention of external partnerships or third-party branding. The company's focus on in-house R&D and manufacturing ensures control over product quality and pricing, supporting consistent revenue generation from its established customer base. Yunnan Botanee Bio-Technology Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Yunnan Botanee Bio-Technology Group Co stock

Current Assets of Yunnan Botanee Bio-Technology Group Co is 691.60 M CNY in 2025.

Current Assets of Yunnan Botanee Bio-Technology Group Co changed from 6.27 B CNY to 691.60 M CNY, representing a -88.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Yunnan Botanee Bio-Technology Group Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Yunnan Botanee Bio-Technology Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Yunnan Botanee Bio-Technology Group Co

All Key Metrics — Yunnan Botanee Bio-Technology Group Co